A SECONDARY ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF V116, A PNEUMOCOCCAL CONJUGATE VACCINE, IN CHILDREN AND ADOLESCENTS WITH INCREASED RISK OF PNEUMOCOCCAL DISEASE (STRIDE-013) (ID 847)

Jagannath V, Pathirana J, Chapman T, Zeng T, Euler D, Papa M, Fernsler D, Park J, Esteves-Jaramillo A, Platt H, for the STRIDE-013 study group. Presented on behalf of the authors by Patel J

MSD (UK)

This abstract was previously presented at ISPPD-14 in Copenhagen, Denmark, on 17-21 May 2026

Funding: This porject was funded by Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA

Conflicts of interest: The authors are employees of Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA and MSD (UK) Limited, London, UK